| U.S.
Securities and Exchange Commission 100 F Street, N.E. Washington, DC 201549 |
Fresenius
Medical Care AG POB 61346 Bad Homburg Germany www.freseniusmedicalcare.com |
February 24, 2026
| Re: | Notice of Disclosure Filed in Exchange Act Annual Report Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act |
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Fresenius Medical Care AG has made disclosure pursuant to such provisions in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on February 24, 2026. Such disclosure begins on page 40 of the Annual Report on Form 20-F and is incorporated by reference herein.
Sincerely,
| By: | /s/ Martin Fischer | |
| Name: | Martin Fischer | |
| Title: | Chief Financial Officer and member of the Management Board |
Fresenius Medical Care AG, 61346 Bad Homburg, Germany, T +49 6172 609-0, Registered Office and
Commercial Register: Hof (Saale), HRB 6841, VAT-ID No.: DE 811127677, Chair of Supervisory Board: Michael Sen
Management Board: Helen Giza (Chair), Martin Fischer, Charles Hugh-Jones, Joseph E. Turk, Craig Cordola. Bank Account: Commerzbank AG, Frankfurt/Main, IBAN: DE23 5008 0000 0711 6731 00, SWIFT/BIC: DRESDEFF501